NMDA receptors are not necessary for burst firing of lateral habenula neurons in mice - Report - MDSpire

NMDA receptors are not necessary for burst firing of lateral habenula neurons in mice

  • By

  • Rong Zhou

  • Jingjing Lu

  • Yunxiang Ling

  • Hong Wang

  • Lijun Cui

  • Yongliang Pan

  • Huanxin Chen

  • June 11, 2026

  • 0 min

Share

Clinical Report: Lateral Habenula Neurons in Mice Do Not Require NMDA Receptors for Burst Firing

Overview

This study investigates the role of N-methyl-D-aspartate receptors (NMDARs) in burst firing of lateral habenula (LHb) neurons in mice. Findings indicate that burst firing persists even in the presence of NMDAR antagonists.

Background

The lateral habenula (LHb) is implicated in the pathophysiology of depression, with increased activity observed in depressive states. Burst firing in LHb neurons is associated with stress and depression.

Data Highlights

No numerical data or trial data was presented in the article.

Key Findings

  • Spontaneous burst firing in LHb neurons persists in the presence of the NMDAR antagonist D-AP5.
  • No significant differences were observed in burst firing frequency or spike number per burst between control and D-AP5 conditions.
  • Rebound burst firing was unaffected by D-AP5 or MK-801, another NMDAR antagonist.
  • The study challenges previous reports suggesting that NMDARs are essential for burst firing in LHb neurons.
  • Future research is needed to clarify the role of NMDARs in LHb burst firing under various conditions.

Clinical Implications

The findings indicate that targeting NMDARs may not modulate burst firing in LHb neurons.

Conclusion

The study concludes that NMDARs are not necessary for burst firing in LHb neurons.

Related Resources & Content

  1. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults
  2. NICE Recommendations | Esketamine nasal spray for treatment-resistant depression
  3. HIGHLIGHTS OF PRESCRIBING INFORMATION
  4. Interdisciplinary, Delphi-driven consensus guidelines on the use of intravenous ketamine infusions for depressive disorders from the American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP3)
  5. Acta Neuropathologica — Hyperphosphorylated tau impairs excitability in hippocampal CA1 neurons by altering the axon initial segment's position
  6. Brain — N-methyl-d-aspartate receptor hypofunction causes recurrent and transient failures of perceptual inference
  7. Acta Neuropathologica — Alterations in astrocytic calcium signaling and gliotransmitter release observed in mouse models of α-synucleinopathies
  8. Acta Neuropathologica — Depletion of Neurofilaments Enhances Microtubule Dynamics Through Regulation of Stat3/Stathmin Pathways
  9. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: Réseau canadien pour les traitements de l'humeur et de l'anxiété (CANMAT) 2023 : Mise à jour des lignes directrices cliniques pour la prise en charge du trouble dépressif majeur chez les adultes - PMC
  10. 1 Recommendations | Esketamine nasal spray for treatment-resistant depression | Guidance | NICE
  11. HIGHLIGHTS OF PRESCRIBING INFORMATION
  12. Interdisciplinary, Delphi-driven consensus guidelines on the use of intravenous ketamine infusions for depressive disorders from the American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP3) - ScienceDirect
  13. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study - PubMed
  14. Esketamine Prevents Treatment-Resistant Depression Relapse
  15. Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or Behavior - PMC
  16. Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis | American Journal of Psychiatry
  17. Relative effectiveness of antidepressant treatments in treatment-resistant depression: a systematic review and network meta-analysis of randomized controlled trials | Neuropsychopharmacology
  18. A meta-analysis of the effects of ketamine on suicidal ideation in depression patients - PMC
  19. Intravenous ketamine versus esketamine for depression: a systematic review and meta-analysis

Original Source(s)

Related Content